SCM
ABBV icon

SCS Capital Management’s AbbVie ABBV Stock Holding History

SCS Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45M Buy
13,708
+126
+0.9% +$27.1K 0.03% 177
2026
Q1 		$2.95M Sell
13,582
-1,473
-10% -$327K 0.03% 179
2025
Q4 		$3.44M Buy
15,055
+75
+0.5% +$17.1K 0.04% 171
2025
Q3 		$3.47M Sell
14,980
-9,598
-39% -$1.95M 0.04% 173
2025
Q2 		$4.56M Buy
24,578
+6,978
+40% +$1.3M 0.05% 164
2025
Q1 		$3.69M Buy
+17,600
New +$3.42M 0.05% 143

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCS Capital Management's ABBV Position: Q2 2026 in Review

SCS Capital Management increased its AbbVie (ABBV) stake by 0.93% in Q2 2026, buying an estimated $27.1K and bringing the position to 13,708 shares worth $3.45M. The position accounts for 0.03% of the portfolio, ranked #177.

SCS Capital Management first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.56M in Q2 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SCS Capital Management held 13,708 shares of AbbVie worth $3.45M as of Q2 2026.
  • SCS Capital Management bought 126 AbbVie shares in Q2 2026, an estimated $27.1K.
  • AbbVie made up 0.03% of SCS Capital Management's portfolio in Q2 2026, its #177 holding.
  • SCS Capital Management first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's AbbVie position peaked at $4.56M in Q2 2025.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.